The Effects of Comflor multi-strain probiotics on disease status in ulcerative colitis patients

The Effects of Comflor multi-strain probiotics on disease status in ulcerative colitis patients: a randomized controlled double blind clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210113050024N2

Enrollment

Registered

2021-04-19

Start date

2021-07-22

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis. Ulcerative colitis, unspecified, without complications

Interventions

Intervention 1: Intervention group: consuming 2 cap COMFLOR from FARABIOTIC co. daily after the main meal for 4 months. Intervention 2: Control group: consuming 2 cap PLACEBO from FARABIOTIC co. dail

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The patients with ulcerative colitis in mild or moderate stage

Exclusion criteria

Exclusion criteria: Using antibiotics, probiotics or prebiotics during the past 3 months Having diabetes, liver diseases, kidney diseases, or cardio vascular diseases

Design outcomes

Primary

Measure	Time frame
Quality of life. Timepoint: at the first of study and at the end of month 4. Method of measurement: IBDQ-9? Questionnaire.;Symptoms of disease. Timepoint: at the first of study and at the end of month 4. Method of measurement: Lightiger Questionnaire.;Calprotectin. Timepoint: at the first of study and at the end of month 4. Method of measurement: ELISA lab test.;C reactive protein. Timepoint: at the first of study and at the end of month 4. Method of measurement: Autoanalyzer.	—

Measure

Time frame

Quality of life. Timepoint: at the first of study and at the end of month 4. Method of measurement: IBDQ-9? Questionnaire.;Symptoms of disease. Timepoint: at the first of study and at the end of month 4. Method of measurement: Lightiger Questionnaire.;Calprotectin. Timepoint: at the first of study and at the end of month 4. Method of measurement: ELISA lab test.;C reactive protein. Timepoint: at the first of study and at the end of month 4. Method of measurement: Autoanalyzer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazila Kassaian

Esfahan University of Medical Sciences

nkassaian@gmail.com+98 31 3237 4705

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026